ANI Pharmaceuticals (ANIP) FY2019 results: revenue $207 million, up 2.5% on the year
ANI Pharmaceuticals Inc. (ANIP) reported revenue of $207 million for fiscal 2019, the year ended 31 December 2019, up 2.5% on the year before. Net income was $6 million, down 60.7%, and diluted earnings per share $0.50. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2020.
Revenue
$207 million
+2.5% on the year
FY2012FY2019
Operating margin
7.9%
17.5% a year earlier
FY2012FY2019
Net income
$6 million
-60.7% on the year
FY2012FY2019
Diluted EPS
$0.50
-61.5% on the year
FY2012FY2019
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Revenue
207
202
177
+2.5%
Cost of revenue
63.2
73.0
79.0
-13.5%
Gross profit
143
129
97.8
+11.5%
Gross margin
69.4%
63.8%
55.3%
Research and development
19.8
15.4
9.1
+28.7%
Selling, general and administrative
55.8
44.1
31.6
+26.7%
Operating income
16.4
35.4
28.3
-53.8%
Operating margin
7.9%
17.5%
16.0%
Interest expense
13.5
14.9
11.3
-9.7%
Pre-tax income
3.2
20.1
16.3
-84.3%
Income tax
-2.9
4.6
17.4
Effective tax rate
-93.0%
22.7%
106.6%
Net income
6.1
15.5
-1.1
-60.7%
Net margin
3.0%
7.7%
-0.6%
Diluted EPS
$0.50
$1.30
-$0.09
-61.5%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Operating cash flow
45.6
67.1
39.4
-32.0%
Capital expenditure
6.6
5.7
10.4
+15.5%
Free cash flow
39.0
61.3
29.1
-36.4%
Free cash flow margin
18.9%
30.4%
16.4%
Cash from investing
-27.5
-27.4
-108
Cash from financing
1.2
-27.8
72.4
Depreciation and amortisation
44.6
33.7
27.9
+32.2%
Share-based compensation
9.2
6.8
6.1
+35.9%
Buybacks
1.0
0.0
0.0
Dividends paid
0.0
n/a
n/a
Diluted shares, weighted
12m
12m
12m
+2.3%
Balance sheet
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Shareholders' equity
213
197
175
+7.9%
Debt
186
183
202
+1.5%
Operating lease liabilities
0.3
n/a
n/a
Other liabilities
58.0
50.3
35.9
+15.2%
Total liabilities and equity
457
431
412
+6.1%
Fixed assets
40.6
38.1
20.4
+6.5%
Goodwill
3.6
3.6
1.8
0.0%
Intangible assets
180
202
230
-10.5%
Cash and equivalents
62.3
43.0
31.1
+44.9%
Receivables
72.1
64.8
58.8
+11.2%
Inventory
48.2
40.5
37.7
+18.9%
Other assets
49.6
39.0
32.4
+27.4%
Total assets
457
431
412
+6.1%
10-K for the year ended 31 December 2019, filed 27 February 2020: the filing.